New York, Jan 22, 2026, 8:47 PM EST — Market closed.
- AbbVie shares ended Thursday 0.9% higher, following a wider bounce in U.S. stocks.
- Attention turns to AbbVie’s February 4 earnings and 2026 forecast, where guidance will probably steer the narrative.
- Macro watch: inflation figures and the Federal Reserve’s Jan. 27-28 meeting remain key as interest rates stay in focus.
AbbVie Inc (ABBV.N) shares climbed 0.9% Thursday, finishing at $218.11. The stock traded in a range from $214.81 to $219.04, with roughly 5.7 million shares exchanged.
U.S. markets remain closed until Friday, leaving AbbVie’s next move more likely driven by pre-market developments — rate forecasts, policy news, and the kickoff of a busy earnings season — than by Thursday’s close.
AbbVie’s Feb. 4 earnings report carries weight as investors want more than just past numbers—they’re after clear signals on demand and pricing for 2026.
Thursday’s trading looked like a relief rally in risk assets following President Donald Trump’s retreat from his Greenland threats. “The Greenland story is dominating everything else,” said Rick Meckler, partner at Cherry Lane Investments. (Reuters)
Markets digested delayed U.S. economic data following the government shutdown. The latest report showed consumer spending climbed 0.5% in November, while the personal consumption expenditures (PCE) price index — the Fed’s favored inflation measure — rose 2.8% year-over-year. (Reuters)
The macro calendar remains packed. The Federal Reserve’s policy-setting committee is scheduled to meet Jan. 27-28, with a decision expected on Jan. 28. (Federal Reserve)
AbbVie will release its full-year and fourth-quarter 2025 results on Feb. 4, ahead of the market open. The company is set to host a webcast of its earnings call at 8 a.m. Central time. (AbbVie News Center)
Big pharma remains under scrutiny. On Wednesday, Johnson & Johnson projected 2026 profit and sales to surpass Wall Street estimates. CFO Joseph Wolk noted a recent U.S. drug-pricing agreement would hit the company for “hundreds of millions of dollars,” highlighting how policy shifts feed into their guidance. (Reuters)
AbbVie faces straightforward risks: a cautious 2026 outlook, pricing that falls short of expectations, or any pipeline and competitive updates that don’t reassure investors. In a market driven by headlines, even defensives aren’t immune to that kind of uncertainty.
Traders head into Friday eyeing if the broad rebound can stick and whether healthcare stays in step if rates shift once more. The bigger event looms on Feb. 4, when AbbVie reports ahead of the opening bell.
